Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Cost of RevenueEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsReceivables - NetReceivables - OtherShares Repurchased
Ratios

Corcept Therapeutics (CORT) Receivables - Net (2016 - 2025)

Corcept Therapeutics' Receivables - Net history spans 10 years, with the latest figure at $59.8 million for Q4 2025.

  • For Q4 2025, Receivables - Net rose 10.76% year-over-year to $59.8 million; the TTM value through Dec 2025 reached $59.8 million, up 10.76%, while the annual FY2025 figure was $59.8 million, 10.76% up from the prior year.
  • Receivables - Net for Q4 2025 was $59.8 million at Corcept Therapeutics, down from $69.6 million in the prior quarter.
  • Across five years, Receivables - Net topped out at $69.6 million in Q3 2025 and bottomed at $22.2 million in Q1 2021.
  • The 5-year median for Receivables - Net is $33.6 million (2023), against an average of $42.3 million.
  • The largest annual shift saw Receivables - Net dropped 16.8% in 2021 before it soared 88.95% in 2024.
  • A 5-year view of Receivables - Net shows it stood at $27.6 million in 2021, then rose by 12.42% to $31.1 million in 2022, then soared by 32.41% to $41.1 million in 2023, then skyrocketed by 31.26% to $54.0 million in 2024, then rose by 10.76% to $59.8 million in 2025.
  • Per Business Quant, the three most recent readings for CORT's Receivables - Net are $59.8 million (Q4 2025), $69.6 million (Q3 2025), and $64.6 million (Q2 2025).